Abstract
Leptin has emerged as a major regulator of body adiposity. The majority of humans with obesity have a resistance to leptin. Human and rodent studies indicate that the major cause of this resistance arises from an impaired ability of leptin to cross the blood-brain barrier, with lesser roles played by receptor and post-receptor defects. Evidence from baboons living in the wild is consistent with the hypothesis that during most of evolution serum levels of leptin were much lower than those currently considered normal. Leptin may have evolved to signal to the brain when caloric reserves were adequate to engage in reproductive and other behaviors not immediately concerned with acquisition of calories. The leptin transporter is a regulated system, with the rate of transport being increased by alpha-1 adrenergic agents and decreased by starvation. Impaired regulation of the transporter or impairments in transporter production could underlie the resistance caused by transporter defects. Evolutionary pressures would not have selected against such impairments if leptin levels were lower than those typically seen in Western society. A model that could explain how leptin transporter resistance can be acquired is presented.
Keywords: leptin,, obesity,, blood-brain barrier,, cerebrospinal fluid,, resistance,, transport
Current Pharmaceutical Design
Title: Is Obesity a Disease of the Blood-Brain Barrier? Physiological, Pathological, and Evolutionary Considerations
Volume: 9 Issue: 10
Author(s): William A. Banks
Affiliation:
Keywords: leptin,, obesity,, blood-brain barrier,, cerebrospinal fluid,, resistance,, transport
Abstract: Leptin has emerged as a major regulator of body adiposity. The majority of humans with obesity have a resistance to leptin. Human and rodent studies indicate that the major cause of this resistance arises from an impaired ability of leptin to cross the blood-brain barrier, with lesser roles played by receptor and post-receptor defects. Evidence from baboons living in the wild is consistent with the hypothesis that during most of evolution serum levels of leptin were much lower than those currently considered normal. Leptin may have evolved to signal to the brain when caloric reserves were adequate to engage in reproductive and other behaviors not immediately concerned with acquisition of calories. The leptin transporter is a regulated system, with the rate of transport being increased by alpha-1 adrenergic agents and decreased by starvation. Impaired regulation of the transporter or impairments in transporter production could underlie the resistance caused by transporter defects. Evolutionary pressures would not have selected against such impairments if leptin levels were lower than those typically seen in Western society. A model that could explain how leptin transporter resistance can be acquired is presented.
Export Options
About this article
Cite this article as:
Banks A. William, Is Obesity a Disease of the Blood-Brain Barrier? Physiological, Pathological, and Evolutionary Considerations, Current Pharmaceutical Design 2003; 9 (10) . https://dx.doi.org/10.2174/1381612033455350
DOI https://dx.doi.org/10.2174/1381612033455350 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development and a Practical Synthesis of Nepafenac Intermediate via Modified Gassman Reaction
Letters in Organic Chemistry Anti-Inflammatory Gene Therapy for Cardiovascular Disease
Current Gene Therapy Microglial Senescence
CNS & Neurological Disorders - Drug Targets Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Current Pharmaceutical Design Drugs of Abuse and Oxidative Stress in the Brain: From Animal Models to Human Evidence
Mini-Reviews in Organic Chemistry Neutrophil F-actin Dynamics in Familial Mediterranean Fever: The Unequal Effect of Colchicine on Activated Neutrophils
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic: Non-Reproductive Effects of Sex Steroids: Their Immunoregulatory Role (Guest Editor: Jorge Morales-Monto)]
Current Topics in Medicinal Chemistry Capsaicin and Its Analogues: Structure-Activity Relationship Study
Current Medicinal Chemistry Formulation of Nanoparticles Against TB - A Review
Recent Patents on Inflammation & Allergy Drug Discovery PPARα/HNF4α Interplay on Diversified Responsive Elements. Relevance in the Regulation of Liver Peroxisomal Fatty Acid Catabolism
Current Drug Metabolism Editorial: New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection and HCV Extrahepatic Manifestations
Current Drug Targets Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
Medicinal Chemistry Reviews - Online (Discontinued) Prophylaxis of Venous Thromboembolism in Major Orthopedic Surgery: A Practical Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacogenetics of Therapy in Inflammatory Bowel Disease Patients
Current Pharmacogenomics Molecular Modeling Based Synthesis and Evaluation of <i>In vitro</i> Anticancer Activity of Indolyl Chalcones
Current Topics in Medicinal Chemistry Metabolism in Patients with Rheumatoid Arthritis: Resting Energy Expenditure, Physical Activity and Diet-Induced Thermogenesis. Invited Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Chemistry and Pharmacology of Tetrahydropyridines
Current Medicinal Chemistry Soluble Factors of Amnion-Derived Cells in Treatment of Inflammatory and Fibrotic Pathologies
Current Stem Cell Research & Therapy Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Vesicular Carriers for Skin Drug Delivery: The Pheroid™ Technology
Current Pharmaceutical Design